World's First Endoscopic Ablation System

[Guest guest]

CardioFocus to Present at Medtech Insight's ``Investment In Innovation''

Conference

Medtech Insight 2005 In3 San Francisco Conference

SAN FRANCISCO--(BUSINESS WIRE)--June 2, 2005--CardioFocus has announced

that it will be presenting at 2:30 p.m. at Medtech Insight's Prestigious

" Investment In Innovation (In3): A Preview of Early-Stage Medical Technology

Companies " Conference, taking place June 14-15, 2005 at The Palace Hotel in San

Francisco, CA.

CardioFocus, Inc., a privately held company, reports initial clinical

experience with world's first Endoscopic Ablation System for Atrial

Fibrillation. CardioFocus, Inc., an emerging company and technology leader in

laser ablation, announced four-month results from its initial clinical

investigation. Nine patients with paroxysmal atrial fibrillation were treated

with a novel percutaneous therapy designed to electrically isolate the pulmonary

veins. Following a 60-day blanking period, 7/9 patients were free from

symptomatic AF episodes greater than 1 min through 16 weeks follow-up. The 3-mo

CT revealed a mean change in PV diameter of -1 +/- 14% and there was no

symptomatic PV stenosis.

Speaking from Venice, Italy, Natale, MD of the Cleveland Clinic,

reported the successful treatment of 93% of the veins targeted with the laser

system. " I was very satisfied with our ability to access 100% of the anatomical

targets and use the laser system to achieve electrical isolation in 15 of 16

veins. The real-time, anatomical view using the Endoscopic Ablation System

provides a very unique opportunity to tailor ablation therapy in a highly

unpredictable setting. "

The pre-IDE investigation began in Prague, Czech Republic where Vivek

Reddy, MD, of the Massachusetts General Hospital tackled the first cases. Dr.

Reddy was eager to test his extensive in vivo experience with the catheter and

assess the feasibility of using the device as the sole clinical intervention for

patients suffering from drug refractory atrial fibrillation. " Today, there are

no devices approved to treat this challenging arrhythmia. Multiple products are

being used to pursue a variety of different strategies that often amount to a

'shot in the dark.' The CardioFocus technique has documented the difficult

navigational issues clinicians face and provided a new capability to overcome

these obstacles. "

The CardioFocus system brings new capability into the hands of the

electrophysiologist. " The essence of this product is to let the arrhythmia

specialist see the actual anatomy and then use his own eyes and judgment to

select where to direct the energy, " said Sagon, President & CEO. The

CardioFocus device shares a common origin with Optimaze, a surgical laser

ablation product developed by CardioFocus for Lifesciences Corporation.

Atrial fibrillation is the most common cardiac arrhythmia affecting 2.3

million people in the U.S. and 4.5 million people in the developed world.

Characterized by a disorganized and ineffective contraction of the upper

chambers of the heart, AF presents rapid and irregular heartbeats, often causes

discomfort, lightheadedness and/or shortness of breath and carries a very high

risk of stroke.

Medtech Insight, a division of Windhover Information Inc., is the leading

provider of business information and market intelligence for the medical

technology marketplace. To register for the " Investment In Innovation "

conference or for more information on Medtech Insight, please call Kristy Grimes

at , e-mail kristy@..., or visit

www.medtechinsight.com.

Contacts

CardioFocus, Inc.

W. Sagon,